Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
[EN] NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF<br/>[FR] NOUVEAU COMPOSÉ UTILISÉ EN TANT QU'INHIBITEUR DE PROTÉINE KINASE, ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
申请人:HK INNO N CORP
公开号:WO2020101382A1
公开(公告)日:2020-05-22
The present invention provides a novel compound having a protein kinase inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof. The compound according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof are effective in preventing or treating protein kinase-related diseases such as cancers, autoimmune diseases, neurological diseases, metabolic diseases, infections or the like by showing a protein kinase inhibitory activity.
Asymmetric Michael reaction of α-cyano carboxylates catalyzed by a rhodium complex with trans-chelating chiral diphosphine PhTRAP
作者:Masaya Sawamura、Hitoshi Hamashima、Yoshihiko Ito
DOI:10.1016/s0040-4020(01)89377-7
日期:1994.4
AsymmetricMichael reaction of 2-cyanopropionates with vinyl ketones or acrolein in the presence of 0.1–1 mol% of a rhodium catalyst prepared in situ from RhH(CO)(PPh3)3 and a trans-chelatingchiraldiphosphineligand (S,S)-(R,R)-PhTRAP in benzene at 3–5°C gave optically active Michael adducts with high enantiomeric excesses (83–93% ee) in high yields. The reaction of 2-cyanopropionate with methacrolein